Advertisement
U.S. markets close in 36 minutes
  • S&P 500

    5,261.17
    +12.68 (+0.24%)
     
  • Dow 30

    39,830.90
    +70.82 (+0.18%)
     
  • Nasdaq

    16,401.67
    +2.15 (+0.01%)
     
  • Russell 2000

    2,123.74
    +9.39 (+0.44%)
     
  • Crude Oil

    83.07
    +1.72 (+2.11%)
     
  • Gold

    2,241.50
    +28.80 (+1.30%)
     
  • Silver

    24.97
    +0.21 (+0.86%)
     
  • EUR/USD

    1.0789
    -0.0041 (-0.38%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2622
    -0.0016 (-0.13%)
     
  • USD/JPY

    151.3990
    +0.1530 (+0.10%)
     
  • Bitcoin USD

    70,742.61
    +1,931.84 (+2.81%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

FDA approves Bayer's Adempas for two forms of pulmonary hypertension

The FDA approved Adempas to treat adults with two forms of pulmonary hypertension. The FDA reviewed Adempas under its priority review program, which provides for an expedited six-month review of drugs that may offer major advances in treatment. Adempas is marketed by Bayer HealthCare Pharmaceuticals.

Advertisement